| Similar Articles |
|---|
 |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test.   |
The Motley Fool
September 24, 2008
Brian Orelli |
100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in. |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
November 30, 2010
Brian Orelli |
Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
The Motley Fool
December 20, 2011
Brian Orelli |
What's Up With the Back-Slapping, Sequenom? Some sales numbers would be nice. |
The Motley Fool
October 6, 2010
Jeremy Phillips |
Reasons to Sell Sequenom Today Over the past 12 months, Sequenom has risen 115.7% versus an S&P 500 return of 11.3%. Investors in Sequenom have every reason to be proud of their returns. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
Chemistry World
January 8, 2013
Andrew Turley |
Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities. |
The Motley Fool
August 16, 2011
Jeremy Phillips |
Read This Before You Think About Selling Sequenom I consider a debt-to-equity ratio below 50% to be healthy, though the number varies by industry. Sequenom is currently below this level, at 1.1%. |
The Motley Fool
February 13, 2009
Brian Orelli |
Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered. |
The Motley Fool
February 18, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?: Seagate Technology... Prospect Capital... Interactive Intelligence... Sequenom... 99 Cents Only Stores... |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
September 30, 2009
Brian Orelli |
Call Me a Wimp, but I'm Still Nervous Can the mud Sequenom seems to be running in turn to quicksand? |
The Motley Fool
February 4, 2009
Brian Orelli |
43% Growth! Yee-Haw! Illumina rocks another quarter. |
